CRISPR-Edited immune cells battle tough cancers in new trial
NCT ID NCT05795595
Summary
This study tested a new type of cell therapy called CTX131 for adults with advanced solid tumors that have returned or stopped responding to standard treatments. CTX131 uses a patient's own immune cells that are genetically modified in a lab to better target and fight cancer cells. The main goals were to find a safe dose and see if the treatment could shrink tumors in patients with several types of difficult-to-treat cancers.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site 1
Nashville, Tennessee, 37203, United States
-
Research Site 2
St Louis, Missouri, 63110, United States
-
Research Site 3
Duarte, California, 91010, United States
-
Research Site 4
Durham, North Carolina, 27710, United States
-
Research Site 5
Houston, Texas, 77030, United States
-
Research Site 6
Boston, Massachusetts, 02215, United States
-
Research Site 7
Chicago, Illinois, 60637, United States
Conditions
Explore the condition pages connected to this study.